Cargando…
The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies
The safety and tolerability of vortioxetine in adults with major depressive disorder was assessed. Tolerability was based on the nature, incidence and severity of treatment-emergent adverse events (TEAEs) during acute (6/8) week treatment in 11 randomized, double-blind placebo-controlled short-term...
Autores principales: | Baldwin, David S, Chrones, Lambros, Florea, Ioana, Nielsen, Rebecca, Nomikos, George G, Palo, William, Reines, Elin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794082/ https://www.ncbi.nlm.nih.gov/pubmed/26864543 http://dx.doi.org/10.1177/0269881116628440 |
Ejemplares similares
-
Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study
por: Jacobsen, Paula L., et al.
Publicado: (2015) -
Efficacy of vortioxetine on the physical symptoms of major depressive
disorder
por: Christensen, Michael Cronquist, et al.
Publicado: (2018) -
Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study
por: Alam, Mohammed Y., et al.
Publicado: (2014) -
Effectiveness of vortioxetine for major depressive disorder in real-world clinical practice: US cohort results from the global RELIEVE study
por: Mattingly, Gregory, et al.
Publicado: (2023) -
A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders
por: Findling, Robert L., et al.
Publicado: (2018)